Univariable Analysis | Multivariable Analysis | |||||||
---|---|---|---|---|---|---|---|---|
HR | (95 % CI) | P | Global P | aHR | (95 % CI) | P | Global P | |
PDR resistant vs no PDR/susceptible | 1.78 | (0.89–3.54) | 0.101 | 1.42 | (0.62–3.24) | 0.400 | ||
Sex (male vs female) | 1.06 | (0.71–1.60) | 0.770 | 1.45 | (0.91–2.31) | 0.117 | ||
Age (per additional year) | 0.89 | (0.84–0.93) | 0.000 | 0.88 | (0.82–0.95) | 0.0005 | ||
Origin (ref Europe) | 0.029 | 0.720 | ||||||
Africa | 0.40 | (0.20–0.78) | 0.008 | 1.14 | (0.49–2.62) | 0.759 | ||
Asia | 0.73 | (0.45–1.18) | 0.197 | 1.02 | (0.464–2.25) | 0.960 | ||
Other/unknown | 1.10 | (0.58–2.09) | 0.764 | 0.65 | (0.28–1.50) | 0.313 | ||
Previous AIDS diagnosis (yes vs no) | 1.18 | (0.73–1.91) | 0.495 | 1.00 | (0.56–1.76) | 0.986 | ||
Pretreatment CD4 count (per 100 cells/mm3) | 1.01 | (0.98–1.04) | 0.510 | 0.96 | (0.92–1.00) | 0.048 | ||
Pretreatment viral load (per 1 log10 copies/mL increase) | 1.16 | (0.90–1.50) | 0.254 | 0.99 | (0.76–1.28) | 0.987 | ||
Subtype (non B vs B) | 0.85 | (0.48–1.50) | 0.569 | 0.70 | (0.34–1.45) | 0.335 | ||
Year of treatment start (ref: 2007–2008) | 0.018 | 0.818 | ||||||
1998–1999 | 3.14 | (1.22–8.07) | 0.018 | 1.11 | (0.25–4.95) | 0.891 | ||
2000–2002 | 2.01 | (0.71–5.70) | 0.190 | 1.89 | (0.48–7.40) | 0.361 | ||
2003–2004 | 1.97 | (0.75–5.21) | 0.170 | 1.29 | (0.34–4.96) | 0.710 | ||
2005–2006 | 1.36 | (0.52–3.60) | 0.532 | 1.27 | (0.34–4.79) | 0.7230 | ||
Antiretroviral drug combination (ref: NNRTI plus ≥ 2NRTIs) | 0.0002 | 0.007 | ||||||
Unboosted PI plus ≥ 2NRTIs | 19.5 | (2.68; 1.73) | <0.001 | 3.65 | (1.65; 8.05) | 0.001 | ||
Boosted PI plus ≥ 2NRTIs | 1.26 | (0.56; 2.83) | 0.572 | 1.79 | (0.76; 4.57) | 0.222 | ||
Other | 1.73 | (0.62; 4.85) | 0.300 | 2.65 | (0.90; 7.81) | 0.077 |